HemOnc Today Current Issue
The following articles appeared in the print edition of HemOnc Today.
Table of Contents
- Identification of prognostic markers remains ‘holy grail’ in follicular lymphoma research
-
- Addition of abemaciclib to fulvestrant improves PFS in advanced breast cancer
- Alectinib extends PFS in advanced ALK–positive NSCLC
- American Association for Cancer Research inaugurates new leadership
- Beth Israel Deaconess Medical Center appoints dermatology chief
- Carfilzomib regimen extends OS in relapsed multiple myeloma
- City of Hope names provost for clinical faculty
- Memorial Sloan Kettering Cancer Center appoints department chair
- NIH grant to fund research into how lifestyle affects colon cancer outcomes
-
- Olaparib extends PFS in BRCA–mutated metastatic breast cancer
- Radiation oncologist named American Brachytherapy Society fellow
- Task force ‘got it right’ with revised prostate cancer screening recommendation
- White paper outlines progress, challenges of immunotherapy in community setting
- Healthy — and not so healthy — competition John Sweetenham, MD, FRCP, FACP
- FDA approves Keytruda for relapsed, refractory classical Hodgkin lymphoma
- FDA grants fast track designation to ImmunoPulse IL-12 for melanoma
- FDA grants fast track designation to MSC-100-IV for acute GVHD in children
-
- FDA grants orphan drug designation to EDV nanocells for glioblastoma multiforme
- FDA grants priority review to CTL019 for ALL
- FDA lifts clinical hold on trials of vadastuximab talirine for AML
- 177Lu-Dotatate improves PFS, response rate in advanced midgut neuroendocrine tumors
- Alprolix shows promise in treatment of severe pediatric hemophilia B
- Annual report: Overall cancer death rates continue to decline, but problem areas persist
- Dyslipidemia associated with CLL
- Letrozole not superior to anastrozole for breast cancer in postmenopausal women
-
- Medicaid coverage associated with poor outcomes in HNSCC
- Minimal residual disease negativity predicts long-term survival in multiple myeloma
- Most premenopausal women should not undergo oophorectomy due to risks for chronic health conditions
- Pembrolizumab improves OS in advanced urothelial carcinoma
- Preoperative anemia linked to postsurgical mortality in neonates
- Addition of Optune device to temozolomide improves OS in glioblastoma
- BRAF genotypes exhibit different clinical, pathologic profiles
- Gene mutation burden linked to primary site of melanoma
-
- HER-2–targeted therapy effective for treatment-refractory metastatic colorectal cancer
- ‘Huge victory’ for indoor tanning can inform sun protection efforts in average-risk adults
- Indoximod plus pembrolizumab prompts response in advanced melanoma
- Low-dose aspirin reduces risk for many cancers
- ‘Major need’ exists for more effective mucosal melanoma treatments
- Nivolumab improves rate of 5-year OS for patients with advanced NSCLC
- PCP–based screening increases uptake among men, improves detection of thin melanoma
- Radiation prior to immune checkpoint inhibitor therapy may lower toxicity
-
- Does chemotherapy still have a role in follicular lymphoma treatment?